| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H17ClN2O3S |
| Molecular Weight | 376.857 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CCC(=O)NC2=NC3=C(S2)C=C(Cl)C=C3)C=C1OC
InChI
InChIKey=LXFKEVQQSKQXPR-UHFFFAOYSA-N
InChI=1S/C18H17ClN2O3S/c1-23-14-7-3-11(9-15(14)24-2)4-8-17(22)21-18-20-13-6-5-12(19)10-16(13)25-18/h3,5-7,9-10H,4,8H2,1-2H3,(H,20,21,22)
| Molecular Formula | C18H17ClN2O3S |
| Molecular Weight | 376.857 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
KY02111 is a canonical WNT signaling inhibitor. The direct target of KY02111 is still unknown, but results from this study indicate that KY02111 might function downstream from GSK3b and APC in beta-catenin destruction complex. KY02111 promotes differentiation of human pluripotent stem cells to cardiomyocytes and increases in intrinsic stiffness of human trabecular meshwork cells.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
